Diabetes Metab J.  2021 Sep;45(5):641-654. 10.4093/dmj.2021.0220.

Assessment of Insulin Secretion and Insulin Resistance in Human

• Park SY
• Gautier JF
• Chon S

• KMID: 2520848
• DOI: http://doi.org/10.4093/dmj.2021.0220

Abstract

The impaired insulin secretion and increased insulin resistance (or decreased insulin sensitivity) play a major role in the pathogenesis of all types of diabetes mellitus (DM). It is very important to assess the pancreatic β-cell function and insulin resistance/ sensitivity to determine the type of DM and to plan an optimal management and prevention strategy for DM. So far, various methods and indices have been developed to assess the β-cell function and insulin resistance/sensitivity based on static, dynamic test and calculation of their results. In fact, since the metabolism of glucose and insulin is made through a complex process related with various stimuli in several tissues, it is difficult to fully reflect the real physiology. In order to solve the theoretical and practical difficulties, research on new index is still in progress. Also, it is important to select the appropriate method and index for the purpose of use and clinical situation. This review summarized a variety of traditional methods and indices to evaluate pancreatic β-cell function and insulin resistance/sensitivity and introduced novel indices.

Keyword

Diabetes mellitus; Insulin resistance; Insulin secretion

Figure

• 

  Fig. 1. Hyperinsulinemic-euglycemic glucose clamp technique.

Reference

1. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus: present and future perspectives. Nat Rev Endocrinol. 2011; 8:228–36.

2. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004; 88:787–835.

3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837–53.

4. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 2002; 25:1737–43.

5. Moller DE, Flier JS. Insulin resistance: mechanisms, syndromes, and implications. N Engl J Med. 1991; 325:938–48.

6. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008; 294:E15–26.

7. Reaven G. The metabolic syndrome or the insulin resistance syndrome?: different names, different concepts, and different goals. Endocrinol Metab Clin North Am. 2004; 33:283–303.

8. Nielsen JH, Galsgaard ED, Moldrup A, Friedrichsen BN, Billestrup N, Hansen JA, et al. Regulation of beta-cell mass by hormones and growth factors. Diabetes. 2001; 50 Suppl 1:S25–9.

9. Newsholme P, Krause M. Nutritional regulation of insulin secretion: implications for diabetes. Clin Biochem Rev. 2012; 33:35–47.

10. Koeppen BM, Stanton BA. Berne & Levy physiology. 7th ed. Philadelphia: Elsevier;2018.

11. Rorsman P, Renstrom E. Insulin granule dynamics in pancreatic beta cells. Diabetologia. 2003; 46:1029–45.

12. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018; 98:2133–223.

13. Faerch K, Vistisen D, Pacini G, Torekov SS, Johansen NB, Witte DR, et al. Insulin resistance is accompanied by increased fasting glucagon and delayed glucagon suppression in individuals with normal and impaired glucose regulation. Diabetes. 2016; 65:3473–81.

14. Chon S, Gautier JF. An update on the effect of incretin-based therapies on β-cell function and mass. Diabetes Metab J. 2016; 40:99–114.

15. Luzi L, DeFronzo RA. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol. 1989; 257(2 Pt 1):E241–6.

16. Steiner KE, Mouton SM, Bowles CR, Williams PE, Cherrington AD. The relative importance of first- and second-phase insulin secretion in countering the action of glucagon on glucose turnover in the conscious dog. Diabetes. 1982; 31:964–72.

17. Hansen BC, Vinik A, Jen KL, Schielke GP. Fluctuations in basal levels and effects of altered nutrition on plasma somatostatin. Am J Physiol. 1982; 243:R289–95.

18. Ferrannini E, Cobelli C. The kinetics of insulin in man. II. Role of the liver. Diabetes Metab Rev. 1987; 3:365–97.

19. Ferrannini E, Cobelli C. The kinetics of insulin in man. I. General aspects. Diabetes Metab Rev. 1987; 3:335–63.

20. Hansen BC, Striffler JS, Bodkin NL. Decreased hepatic insulin extraction precedes overt noninsulin dependent (type II) diabetes in obese monkeys. Obes Res. 1993; 1:252–60.

21. Hovorka R, Jones RH. How to measure insulin secretion. Diabetes Metab Rev. 1994; 10:91–117.

22. Hovorka R, Soons PA, Young MA. ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed. 1996; 50:253–64.

23. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009; 32(Suppl 2):S157–63.

24. Pacini G, Finegood DT, Bergman RN. A minimal-model-based glucose clamp yielding insulin sensitivity independent of glycemia. Diabetes. 1982; 31(5 Pt 1):432–41.

25. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000; 85:2402–10.

26. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999; 22:1462–70.

27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412–9.

28. Tripathy D, Almgren P, Tuomi T, Groop L. Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care. 2004; 27:2204–10.

29. Ferrannini E, Bjorkman O, Reichard GA Jr, Pilo A, Olsson M, Wahren J, et al. The disposal of an oral glucose load in healthy subjects: a quantitative study. Diabetes. 1985; 34:580–8.

30. Finegood DT, Hramiak IM, Dupre J. A modified protocol for estimation of insulin sensitivity with the minimal model of glucose kinetics in patients with insulin-dependent diabetes. J Clin Endocrinol Metab. 1990; 70:1538–49.

31. Quon MJ, Cochran C, Taylor SI, Eastman RC. Direct comparison of standard and insulin modified protocols for minimal model estimation of insulin sensitivity in normal subjects. Diabetes Res. 1994; 25:139–49.

32. Saad MF, Steil GM, Kades WW, Ayad MF, Elsewafy WA, Boyadjian R, et al. Differences between the tolbutamide-boosted and the insulin-modified minimal model protocols. Diabetes. 1997; 46:1167–71.

33. Beard JC, Bergman RN, Ward WK, Porte D Jr. The insulin sensitivity index in nondiabetic man. Correlation between clampderived and IVGTT-derived values. Diabetes. 1986; 35:362–9.

34. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest. 1987; 79:790–800.

35. Yang YJ, Youn JH, Bergman RN. Modified protocols improve insulin sensitivity estimation using the minimal model. Am J Physiol. 1987; 253(6 Pt 1):E595–602.

36. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol. 1979; 236:E667–77.

37. Cobelli C, Bettini F, Caumo A, Quon MJ. Overestimation of minimal model glucose effectiveness in presence of insulin response is due to undermodeling. Am J Physiol. 1998; 275:E1031–6.

38. Cobelli C, Caumo A, Omenetto M. Minimal model SG overestimation and SI underestimation: improved accuracy by a Bayesian two-compartment model. Am J Physiol. 1999; 277:E481–8.

39. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979; 237:E214–23.

40. Choi CS, Kim C, Lee WJ, Park JY, Hong SK, Lee MG, et al. Association between birth weight and insulin sensitivity in healthy young men in Korea: role of visceral adiposity. Diabetes Res Clin Pract. 2000; 49:53–9.

41. Larsson H, Ahren B. Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine. Diabetologia. 1998; 41:772–7.

42. Choi CS, Kim MY, Han K, Lee MS. Assessment of β-cell function in human patients. Islets. 2012; 4:79–83.

43. Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al. Endotext. South Dartmouth: MDText.com Inc;2021. Chapter, Assessing insulin sensitivity and resistance in humans [cited 2021 Sep 11]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278954.

44. Campbell PJ, Mandarino LJ, Gerich JE. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Metabolism. 1988; 37:15–21.

45. Rizza RA, Mandarino LJ, Gerich JE. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol. 1981; 240:E630–9.

46. Morris AD, Ueda S, Petrie JR, Connell JM, Elliott HL, Donnelly R. The euglycaemic hyperinsulinaemic clamp: an evaluation of current methodology. Clin Exp Pharmacol Physiol. 1997; 24:513–8.

47. Gelfand RA, Barrett EJ. Effect of physiologic hyperinsulinemia on skeletal muscle protein synthesis and breakdown in man. J Clin Invest. 1987; 80:1–6.

48. Greenfield MS, Doberne L, Kraemer F, Tobey T, Reaven G. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes. 1981; 30:387–92.

49. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004; 350:664–71.

50. Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes. 2006; 55:1436–42.

51. Toffolo G, Breda E, Cavaghan MK, Ehrmann DA, Polonsky KS, Cobelli C. Quantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab. 2001; 280:E2–10.

52. Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab . 1980; 51:520–8.

53. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2007; 30 Suppl 1:S42–7.

54. Yasuhara D, Naruo T, Nagai N, Tanaka M, Muranaga T, Nozoe S. Insulinogenic index at 15 min as a marker of nutritional rehabilitation in anorexia nervosa. Am J Clin Nutr. 2003; 77:292–9.

55. Dalla Man C, Campioni M, Polonsky KS, Basu R, Rizza RA, Toffolo G, et al. Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal model assessment of beta-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes. 2005; 54:3265–73.

56. Shen SW, Reaven GM, Farquhar JW. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest. 1970; 49:2151–60.

57. Harano Y, Hidaka H, Takatsuki K, Ohgaku S, Haneda M, Motoi S, et al. Glucose, insulin, and somatostatin infusion for the determination of insulin sensitivity in vivo. Metabolism. 1978; 27(9 Suppl 1):1449–52.

58. Bergman RN, Ader M, Finegood DT, Pacini G. Extrapancreatic effect of somatostatin infusion to increase glucose clearance. Am J Physiol. 1984; 247(3 Pt 1):E370–9.

59. Faber OK, Binder C. C-peptide response to glucagon: a test for the residual beta-cell function in diabetes mellitus. Diabetes. 1977; 26:605–10.

60. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia. 2001; 44:929–45.

61. Pfeifer MA, Graf RJ, Halter JB, Porte D Jr. The regulation of glucose-induced insulin secretion by pre-stimulus glucose level and tolbutamide in normal man. Diabetologia. 1981; 21:198–205.

62. Leighton E, Sainsbury CA, Jones GC. A practical review of cpeptide testing in diabetes. Diabetes Ther. 2017; 8:475–87.

63. Yosten GL, Maric-Bilkan C, Luppi P, Wahren J. Physiological effects and therapeutic potential of proinsulin C-peptide. Am J Physiol Endocrinol Metab. 2014; 307:E955–68.

64. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013; 30:803–17.

65. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 1992; 41:368–77.

66. Saisho Y. Postprandial C-peptide to glucose ratio as a marker of β cell function: implication for the management of type 2 diabetes. Int J Mol Sci. 2016; 17:744.

67. Rijkelijkhuizen JM, Girman CJ, Mari A, Alssema M, Rhodes T, Nijpels G, et al. Classical and model-based estimates of betacell function during a mixed meal vs. an OGTT in a population-based cohort. Diabetes Res Clin Pract. 2009; 83:280–8.

68. Bergman RN, Ader M, Huecking K, Van Citters G. Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes. 2002; 51 Suppl 1:S212–20.

69. Bonadonna RC, Groop L, Kraemer N, Ferrannini E, Del Prato S, DeFronzo RA. Obesity and insulin resistance in humans: a dose-response study. Metabolism. 1990; 39:452–9.

70. Chen H, Sullivan G, Yue LQ, Katz A, Quon MJ. QUICKI is a useful index of insulin sensitivity in subjects with hypertension. Am J Physiol Endocrinol Metab. 2003; 284:E804–12.

71. Bergman RN. Orchestration of glucose homeostasis: from a small acorn to the California oak. Diabetes. 2007; 56:1489–501.

72. Haffner SM, Howard G, Mayer E, Bergman RN, Savage PJ, Rewers M, et al. Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis Study. Diabetes. 1997; 46:63–9.

73. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993; 137:959–65.

74. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998; 83:2694–8.

75. Silfen ME, Manibo AM, McMahon DJ, Levine LS, Murphy AR, Oberfield SE. Comparison of simple measures of insulin sensitivity in young girls with premature adrenarche: the fasting glucose to insulin ratio may be a simple and useful measure. J Clin Endocrinol Metab. 2001; 86:2863–8.

76. Vuguin P, Saenger P, Dimartino-Nardi J. Fasting glucose insulin ratio: a useful measure of insulin resistance in girls with premature adrenarche. J Clin Endocrinol Metab. 2001; 86:4618–21.

77. Quon MJ. Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity. J Clin Endocrinol Metab. 2001; 86:4615–7.

78. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab. 2000; 85:4426–33.

79. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27:1487–95.

80. Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes. 2005; 54:1914–25.

81. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Katz A, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab. 2001; 86:5457–64.

82. Hanley AJ, Williams K, Gonzalez C, D’Agostino RB Jr, Wagenknecht LE, Stern MP, et al. Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study. Diabetes. 2003; 52:463–9.

83. McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, et al. Diagnosing insulin resistance in the general population. Diabetes Care. 2001; 24:460–4.

84. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care. 2000; 23:295–301.

85. Avignon A, Boegner C, Mariano-Goulart D, Colette C, Monnier L. Assessment of insulin sensitivity from plasma insulin and glucose in the fasting or post oral glucose-load state. Int J Obes Relat Metab Disord. 1999; 23:512–7.

86. Gutt M, Davis CL, Spitzer SB, Llabre MM, Kumar M, Czarnecki EM, et al. Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. Diabetes Res Clin Pract. 2000; 47:177–84.

87. Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Mol Genet Metab. 1998; 63:134–41.